TABLE 2.

Follow‐up outcomes of patients under dabigatran and rivaroxaban treatment after IPTW‐adjusted

Follow up length/Outcome	Event rate		Dabigatran vs. Rivaroxaban
	Dabigatran	Rivaroxaban	HR (95% CI) a	p value
3 months follow‐up
Cancer related death	7.7%	12.2%	0.61 (0.36–1.02)	0.059
Secondary outcomes
All‐cause mortality	8.9%	13.7%	0.63 (0.40–0.99)	0.048
Major bleeding	1.1%	3.9%	0.28 (0.14–0.57)	<0.001
Gastrointestinal bleeding	0.7%	2.9%	0.25 (0.11–0.56)	<0.001
6 months follow‐up
Cancer related death	12.8%	19.2%	0.66 (0.45–0.96)	0.028
Secondary outcomes
All‐cause mortality	14.5%	21.5%	0.66 (0.47–0.93)	0.018
Major bleeding	2.5%	5.5%	0.45 (0.25–0.81)	0.008
Gastrointestinal bleeding	1.7%	4.2%	0.40 (0.19–0.85)	0.017
9 months follow‐up
Cancer related death	16.6%	23.4%	0.70 (0.52–0.95)	0.023
Secondary outcomes
All‐cause mortality	18.5%	26.3%	0.70 (0.53–0.92)	0.011
Major bleeding	2.7%	6.1%	0.45 (0.26–0.77)	0.004
Gastrointestinal bleeding	1.7%	4.6%	0.38 (0.19–0.78)	0.009
1‐year follow‐up
Cancer related death	19.4%	26.9%	0.71 (0.54–0.93)	0.012
Secondary outcomes
All‐cause mortality	21.5%	30.2%	0.70 (0.54–0.90)	0.005
Major bleeding	3.5%	6.7%	0.53 (0.33–0.83)	0.006
Gastrointestinal bleeding	2.3%	5.1%	0.46 (0.26–0.83)	0.009
At the end of the follow‐up
Cancer related death	27.7%	33.6%	0.79 (0.64–0.98)	0.029
Secondary outcomes
All‐cause mortality	32.9%	39.1%	0.81 (0.67–0.97)	0.023
Major bleeding	6.2%	9.6%	0.64 (0.47–0.88)	0.006
Gastrointestinal bleeding	4.3%	7.5%	0.57 (0.39–0.84)	0.004

Abbreviations: CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weighting.

^a Estimated using the subdistribution hazard model which considered all‐cause death as a competing risk.